Browse MYO18A

Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Endoplasmic reticulum-Golgi intermediate compartment Cytoplasm, cytoskeleton. Note=Colocalizes with actin.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Note=Lacks the PDZ domain. Diffusely localized in the cytoplasm.; SUBCELLULAR LOCATION: Golgi apparatus. Golgi apparatus, trans-Golgi network. Note=Recruited to the Golgi apparatus by GOLPH3.; SUBCELLULAR LOCATION: Isoform 5: Cell surface
Domain PF00063 Myosin head (motor domain)
PF01576 Myosin tail
PF00595 PDZ domain (Also known as DHR or GLGF)
Function

May link Golgi membranes to the cytoskeleton and participate in the tensile force required for vesicle budding from the Golgi. Thereby, may play a role in Golgi membrane trafficking and could indirectly give its flattened shape to the Golgi apparatus (PubMed:19837035, PubMed:23345592). Alternatively, in concert with LURAP1 and CDC42BPA/CDC42BPB, has been involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration (PubMed:18854160). May be involved in the maintenance of the stromal cell architectures required for cell to cell contact (By similarity). Regulates trafficking, expression, and activation of innate immune receptors on macrophages. Plays a role to suppress inflammatory responsiveness of macrophages via a mechanism that modulates CD14 trafficking (PubMed:25965346). Acts as a receptor of surfactant-associated protein A (SFTPA1/SP-A) and plays an important role in internalization and clearance of SFTPA1-opsonized S.aureus by alveolar macrophages (PubMed:16087679, PubMed:21123169). Strongly enhances natural killer cell cytotoxicity (PubMed:27467939).

> Gene Ontology
 
Biological Process GO:0006900 membrane budding
GO:0007030 Golgi organization
GO:0007163 establishment or maintenance of cell polarity
GO:0009306 protein secretion
GO:0016050 vesicle organization
GO:0030010 establishment of cell polarity
GO:0031032 actomyosin structure organization
GO:0048193 Golgi vesicle transport
GO:0048194 Golgi vesicle budding
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0090161 Golgi ribbon formation
GO:0090162 establishment of epithelial cell polarity
GO:0090164 asymmetric Golgi ribbon formation
GO:1903532 positive regulation of secretion by cell
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0003779 actin binding
GO:0043531 ADP binding
GO:0051015 actin filament binding
Cellular Component GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0005802 trans-Golgi network
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0031984 organelle subcompartment
GO:0042641 actomyosin
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-1839124: FGFR1 mutant receptor activation
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5655302: Signaling by FGFR1 in disease
R-HSA-1839117: Signaling by cytosolic FGFR1 fusion mutants
Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYO18A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYO18A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYO18A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6640.0128
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6950.678
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6390.617
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1360.688
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3070.913
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0840.982
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4640.169
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5120.74
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3620.84
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8280.609
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2980.574
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1240.105
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYO18A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.23.79.50.388
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYO18A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYO18A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYO18A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYO18A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYO18A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYO18A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYO18A
Namemyosin XVIIIA
Aliases KIAA0216; MysPDZ; SP-A receptor subunit SP-R210 alphaS; molecule associated with JAK3 N-terminus; myosin 18A ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYO18A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.